Patents by Inventor Trevor M. Penning

Trevor M. Penning has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Indomethacin analogs for the treatment of castrate-resistant prostate cancer
    Patent number: 11738004
    Abstract: Provided are compositions for inhibiting a biological activity of an aldo-keto reductase family 1, member C3 (AKR1C3) polypeptide. In some embodiments, the compositions are indomethacin derivatives that are AKR1C3-specific inhibitors. Also provided are methods for producing disclosed indomethacin derivatives that substantially lack cyclooxygenase inhibitory activity but that have AKR1C3 inhibitory activity, methods for inhibiting AKR1C3 polypeptide biological activities, and methods for treating prostate tumors in subjects.
    Type: Grant
    Filed: April 21, 2021
    Date of Patent: August 29, 2023
    Assignees: Vanderbilt University, The Trustees of the University of Pennsylvania
    Inventors: Lawrence J. Marnett, Andy J. Liedtke, Trevor M. Penning, Adegoke O. Adeniji, Michael C. Byrns
  • 2-BETA-NAPHTHYL-ACETIC ACID ANALOGS AS AKR1C3 INHIBITORS AND METHODS OF USING SAME
    Publication number: 20230039244
    Abstract: The invention includes 2-?-naphthyl-acetic acid derivatives, which are selective AKR1C3 inhibitors. In certain embodiments, the compounds of the invention are R-naproxen analogs. The invention further includes methods of treating cancer, such as prostate cancer and/or castration-resistant prostate cancer, using at least one compound of the invention.
    Type: Application
    Filed: September 15, 2022
    Publication date: February 9, 2023
    Inventors: Trevor M. PENNING, Adegoke ADENIJI, Lawrence J. MARNETT
  • 2-beta-naphthyl-acetic acid analogs as AKR1C3 inhibitors and methods of using same
    Patent number: 11459295
    Abstract: The invention includes 2-?-naphthyl-acetic acid derivatives, which are selective AKR1C3 inhibitors. In certain embodiments, the compounds of the invention are (R)-naproxen analogs. The invention further includes methods of treating cancer, such as prostate cancer and/or castration-resistant prostate cancer, using at least one compound of the invention.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: October 4, 2022
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, VANDERBILT UNIVERSITY
    Inventors: Trevor M. Penning, Adegoke Adeniji, Lawrence J. Marnett
  • INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER
    Publication number: 20210251960
    Abstract: Provided are compositions for inhibiting a biological activity of an aldo-keto reductase family 1, member C3 (AKR1C3) polypeptide. In some embodiments, the compositions are indomethacin derivatives that are AKR1C3-specific inhibitors. Also provided are methods for producing disclosed indomethacin derivatives that substantially lack cyclooxygenase inhibitory activity but that have AKR1C3 inhibitory activity, methods for inhibiting AKR1C3 polypeptide biological activities, and methods for treating prostate tumors in subjects.
    Type: Application
    Filed: April 21, 2021
    Publication date: August 19, 2021
    Applicants: Vanderbilt University, The Trustees of the University of Pennsylvania
    Inventors: Lawrence J. Marnett, Andy J. Liedtke, Trevor M. Penning, Adegoke O. Adeniji, Michael C. Byrns
  • INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER
    Publication number: 20190350903
    Abstract: Provided are compositions for inhibiting a biological activity of an aldo-keto reductase family 1, member C3 (AKR1C3) polypeptide. In some embodiments, the compositions are indomethacin derivatives that are AKR1C3-specific inhibitors. Also provided are methods for producing disclosed indomethacin derivatives that substantially lack cyclooxygenase inhibitory activity but that have AKR1C3 inhibitory activity, methods for inhibiting AKR1C3 polypeptide biological activities, and methods for treating prostate tumors in subjects.
    Type: Application
    Filed: August 2, 2019
    Publication date: November 21, 2019
    Applicants: Vanderbilt University, The Trustees of the University of Pennsylvania
    Inventors: Lawrence J. Marnett, Andy J. Liedtke, Trevor M. Penning, Adegoke O. Adeniji, Michael C. Byrns
  • Indomethacin analogs for the treatment of castrate-resistant prostate cancer
    Patent number: 10398678
    Abstract: Provided are compositions for inhibiting a biological activity of an aldo-keto reductase family 1, member C3 (AKR1C3) polypeptide. In some embodiments, the compositions are indomethacin derivatives that are AKR1C3-specific inhibitors. Also provided are methods for producing disclosed indomethacin derivatives that substantially lack cyclooxygenase inhibitory activity but that have AKR1C3 inhibitory activity, methods for inhibiting AKR1C3 polypeptide biological activities, and methods for treating prostate tumors in subjects.
    Type: Grant
    Filed: February 19, 2018
    Date of Patent: September 3, 2019
    Assignees: Vanderbilt University, The Trustees of the University of Pennsylvania
    Inventors: Lawrence J. Marnett, Andy J. Liedtke, Trevor M. Penning, Adegoke O. Adeniji, Michael C. Byrns
  • 2-BETA-NAPHTHYL-ACETIC ACID ANALOGS AS AKR1C3 INHIBITORS AND METHODS OF USING SAME
    Publication number: 20180305305
    Abstract: The invention includes 2-?-naphthyl-acetic acid derivatives, which are selective AKR1C3 inhibitors. In certain embodiments, the compounds of the invention are (R)-naproxen analogs. The invention further includes methods of treating cancer, such as prostate cancer and/or castration-resistant prostate cancer, using at least one compound of the invention.
    Type: Application
    Filed: October 21, 2016
    Publication date: October 25, 2018
    Inventors: Trevor M. PENNING, Adegoke ADENIJI, Lawrence J. MARNETT
  • INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER
    Publication number: 20180271835
    Abstract: Provided are compositions for inhibiting a biological activity of an aldo-keto reductase family 1, member C3 (AKR1C3) polypeptide. In some embodiments, the compositions are indomethacin derivatives that are AKR1C3-specific inhibitors. Also provided are methods for producing disclosed indomethacin derivatives that substantially lack cyclooxygenase inhibitory activity but that have AKR1C3 inhibitory activity, methods for inhibiting AKR1C3 polypeptide biological activities, and methods for treating prostate tumors in subjects.
    Type: Application
    Filed: February 19, 2018
    Publication date: September 27, 2018
    Applicants: Vanderbilt University, The Trustees of the University of Pennsylvania
    Inventors: Lawrence J. Marnett, Andy J. Liedtke, Trevor M. Penning, Adegoke O. Adeniji, Michael C. Byrns
  • Bifunctional AKR1C3 inhibitors/androgen receptor modulators and methods of use thereof
    Patent number: 10071953
    Abstract: The invention includes compositions comprising selective AKR1C3 inhibitors. The invention also includes compositions comprising bifunctional AKR1C3 inhibitors and selective androgen receptor modulators. The invention further includes methods of treatment using the compositions of the invention.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: September 11, 2018
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Trevor M. Penning, Adegoke O. Adeniji, Michael C. Byrns, Jeffrey Winkler, Barry Twenter
  • Indomethacin analogs for the treatment of castrate-resistant prostate cancer
    Patent number: 9895351
    Abstract: Provided are compositions for inhibiting a biological activity of an aldo-keto reductase family 1, member C3 (AKR1C3) polypeptide. In some embodiments, the compositions are indomethacin derivatives that are AKR1C3-specific inhibitors. Also provided are methods for producing disclosed indomethacin derivatives that substantially lack cyclooxygenase inhibitory activity but that have AKR1C3 inhibitory activity, methods for inhibiting AKR1C3 polypeptide biological activities, and methods for treating prostate tumors in subjects.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: February 20, 2018
    Assignees: Vanderbilt University, The Trustees of the University of Pennsylvania
    Inventors: Lawrence J. Marnett, Andy J. Liedtke, Trevor M. Penning, Adegoke O. Adeniji, Michael C. Byrns
  • INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER
    Publication number: 20160303082
    Abstract: Provided are compositions for inhibiting a biological activity of an aldo-keto reductase family 1, member C3 (AKR1C3) polypeptide. In some embodiments, the compositions are indomethacin derivatives that are AKR1C3-specific inhibitors. Also provided are methods for producing disclosed indomethacin derivatives that substantially lack cyclooxygenase inhibitory activity but that have AKR1C3 inhibitory activity, methods for inhibiting AKR1C3 polypeptide biological activities, and methods for treating prostate tumors in subjects.
    Type: Application
    Filed: April 19, 2016
    Publication date: October 20, 2016
    Inventors: Lawrence J. Marnett, Andy J. Liedtke, Trevor M. Penning, Adegoke O. Adeniji, Michael C. Byrns
  • Bifunctional AKR1C3 Inhibitors/Androgen Receptor Modulators and Methods of Use Thereof
    Publication number: 20160159731
    Abstract: The invention includes compositions comprising selective AKR1C3 inhibitors. The invention also includes compositions comprising bifunctional AKR1C3 inhibitors and selective androgen receptor modulators. The invention further includes methods of treatment using the compositions of the invention.
    Type: Application
    Filed: January 12, 2016
    Publication date: June 9, 2016
    Inventors: Trevor M. Penning, Adegoke O. ADENIJI, Michael C. BURNS, Jeffrey WINKLER, Barry TWENTER
  • Indomethacin analogs for the treatment of castrate-resistant prostate cancer
    Patent number: 9346803
    Abstract: Provided are compositions for inhibiting a biological activity of an aldoketo reductase family 1, member C3 (AKR1 C3) polypeptide. In some embodiments, the compositions are indomethacin derivatives that are AKR1 C3-specific inhibitors. Also provided are methods for producing disclosed indomethacin derivatives that substantially lack cyclooxygenase inhibitory activity but that have AKR1C3 inhibitory activity, methods for inhibiting AKR1C3 polypeptide biological activities, and methods for treating prostate tumors in subjects.
    Type: Grant
    Filed: October 17, 2012
    Date of Patent: May 24, 2016
    Assignees: Vanderbilt University, The Trustees of the University of Pennsylvania
    Inventors: Lawrence J. Marnett, Andy J. Liedtke, Trevor M. Penning, Adegoke O. Adeniji, Michael C. Byrns
  • Bifunctional AKR1C3 inhibitors/androgen receptor modulators and methods of use thereof
    Patent number: 9271961
    Abstract: The invention includes compositions comprising selective AKR1C3 inhibitors. The invention also includes compositions comprising bifunctional AKR1C3 inhibitors and selective androgen receptor modulators. The invention further includes methods of treatment using the compositions of the invention.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: March 1, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Trevor M. Penning, Adegoke O. Adeniji, Michael C. Burns, Jeffrey Winkler, Barry Twenter
  • INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER
    Publication number: 20140371261
    Abstract: Provided are compositions for inhibiting a biological activity of an aldoketo reductase family 1, member C3 (AKR1 C3) polypeptide. In some embodiments, the compositions are indomethacin derivatives that are AKR1 C3-specific inhibitors. Also provided are methods for producing disclosed indomethacin derivatives that substantially lack cyclooxygenase inhibitory activity but that have AKR1C3 inhibitory activity, methods for inhibiting AKR1C3 polypeptide biological activities, and methods for treating prostate tumors in subjects.
    Type: Application
    Filed: October 17, 2012
    Publication date: December 18, 2014
    Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, VANDERBILT UNIVERSITY
    Inventors: Lawrence J. Marnett, Andy J. Liedtke, Trevor M. Penning, Adegoke O. Adeniji, Michael C. Byrns
  • Bifunctional AKR1C3 Inhibitors/Androgen Receptor Modulators and Methods of Use Thereof
    Publication number: 20140107085
    Abstract: The invention includes compositions comprising selective AKR1C3 inhibitors. The invention also includes compositions comprising bifunctional AKR1C3 inhibitors and selective androgen receptor modulators. The invention further includes methods of treatment using the compositions of the invention.
    Type: Application
    Filed: October 10, 2013
    Publication date: April 17, 2014
    Applicant: The Trustees of The University of Pennsylvania
    Inventors: Trevor M. Penning, Adegoke O. Adeniji, Michael C. Burns, Jeffrey Winkler, Barry Twenter
  • Non-steroid and non-prostanoid inhibitors of steroid and prostaglandin transforming enzymes
    Patent number: 5439943
    Abstract: Compounds such as 1-(4'-nitrophenyl)-2-propen-1-ol are disclosed which are non-steroidal mechanism-based inactivators of rat liver 3.alpha.-hydroxysteroid dehydrogenase. The corresponding ketones are time dependent inactivators of cyclooxygenase (PGH.sub.2 -synthase).
    Type: Grant
    Filed: November 9, 1994
    Date of Patent: August 8, 1995
    Assignee: Trustees of the University of Pennsylvania
    Inventors: Trevor M. Penning, Joseph W. Ricigliano
  • Non-steroid and non-prostanoid inhibitors of steroid and prostaglandin transforming enzymes
    Patent number: 5399790
    Abstract: Compounds such as 1-(4'-nitrophenyl)-2-propen-1-ol are disclosed which are non-steroidal mechanism-based inactivators of rat liver 3.alpha.-hydroxysteroid dehydrogenase. The corresponding ketones are time dependent inactivators of cyclooxygenase (PGH.sub.2 -synthase).
    Type: Grant
    Filed: August 30, 1993
    Date of Patent: March 21, 1995
    Assignee: Trustees of The University of Pennsylvania
    Inventors: Trevor M. Penning, Joseph W. Ricigliano
  • Non-steroid and non-prostanoid inhibitors of steroid and prostaglandin transfroming enzymes
    Patent number: 5258296
    Abstract: Compounds such as 1-(4'-nitrophenyl)-2-propen-1-ol are disclosed which are non-steroidal mechanism-based inactivators of rat liver 3.alpha.-hydroxysteroid dehydrogenase. The corresponding ketones are time dependent inactivators of cyclooxygenase (PGH.sub.2 -synthase).
    Type: Grant
    Filed: September 9, 1991
    Date of Patent: November 2, 1993
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Trevor M. Penning, Joseph W. Ricigliano
  • Irreversible ligands for nonsteroidal antiinflammatory drug and prostaglandin binding sites
    Patent number: 5187187
    Type: Grant
    Filed: February 19, 1991
    Date of Patent: February 16, 1993
    Assignee: Trustees of the University of Pennsylvania
    Inventors: Trevor M. Penning, Leslie J. Askonas